Hormone therapy: Difference between revisions

Line 32:

* SERMs (mentioned in the section above) will completely block breast development.

* Topical non-aromatisable androgens (i.e. that can't be converted into an estrogen) applied to the breast will also block breast development, but ~~it's~~ not as effective as SERMs. There is also a risk of the androgen being distributed to other parts of the body and therefore causing masculinisation elsehwere.<ref>{{Cite journal|last=Kuhn|first=J-M.|last2=Roca|first2=R.|last3=Laudat|first3=Marie-Hélène|last4=Rieu|first4=M.|last5=Luton|first5=J-P.|last6=Bricaire|first6=H.|date=October 1983|title=STUDIES ON THE TREATMENT OF IDIOPATHIC GYNAECOMASTIA WITH PERCUTANEOUS DIHYDROTESTOSTERONE|url=http://doi.wiley.com/10.1111/j.1365-2265.1983.tb00026.x|journal=Clinical Endocrinology|language=en|volume=19|issue=4|pages=513–520|doi=10.1111/j.1365-2265.1983.tb00026.x|issn=0300-0664}}</ref>

* Topical non-aromatisable androgens (i.e. that can't be converted into an estrogen) applied to the breast will also block breast development, but they are not as effective as SERMs. There is also a risk of the androgen being distributed to other parts of the body and therefore causing masculinisation elsehwere.<ref>{{Cite journal|last=Kuhn|first=J-M.|last2=Roca|first2=R.|last3=Laudat|first3=Marie-Hélène|last4=Rieu|first4=M.|last5=Luton|first5=J-P.|last6=Bricaire|first6=H.|date=October 1983|title=STUDIES ON THE TREATMENT OF IDIOPATHIC GYNAECOMASTIA WITH PERCUTANEOUS DIHYDROTESTOSTERONE|url=http://doi.wiley.com/10.1111/j.1365-2265.1983.tb00026.x|journal=Clinical Endocrinology|language=en|volume=19|issue=4|pages=513–520|doi=10.1111/j.1365-2265.1983.tb00026.x|issn=0300-0664}}</ref>

* [[Mastectomy]] (i.e. surgical removal of breasts) will of course prevent breasts from developing. This is an irreversible option.

* Exposing the breasts to radiation is an irreversible process that might block breast development, although it's not as effective as SERMs.<ref>{{Cite journal|last=Viani|first=Gustavo Arruda|last2=Bernardes da Silva|first2=Lucas Godói|last3=Stefano|first3=Eduardo Jose|date=July 2012|title=Prevention of Gynecomastia and Breast Pain Caused by Androgen Deprivation Therapy in Prostate Cancer: Tamoxifen or Radiotherapy?|url=https://linkinghub.elsevier.com/retrieve/pii/S0360301612000806|journal=International Journal of Radiation Oncology*Biology*Physics|language=en|volume=83|issue=4|pages=e519–e524|doi=10.1016/j.ijrobp.2012.01.036}}</ref> This treatment may increase the risk of breast cancer.<ref>{{Cite journal|last=Aksnessæther|first=Bjørg Y.|last2=Solberg|first2=Arne|last3=Klepp|first3=Olbjørn H.|last4=Myklebust|first4=Tor Åge|last5=Skovlund|first5=Eva|last6=Hoff|first6=Solveig Roth|last7=Vatten|first7=Lars J.|last8=Lund|first8=Jo-Åsmund|date=May 2018|title=Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?|url=https://linkinghub.elsevier.com/retrieve/pii/S0360301618302207|journal=International Journal of Radiation Oncology*Biology*Physics|language=en|volume=101|issue=1|pages=211–216|doi=10.1016/j.ijrobp.2018.01.096}}</ref>